Poster Hall
Sponsored by AbbVie Medical Affairs
Conference Perspectives
View all perspectives
David Liew drdavidliew
3 months 2 weeks ago
Bold conclusion from Japan:
laughter improves function in RA.
I like it
Feel like it might be partially a correlation/causation link but if an hour of laughter can push down IL-6 levels in RA patients, time for reimbursement for stand up comedy?
#EULAR2024 POS1029 @RheumNow https://t.co/EpHnX50PgF
Dr. Antoni Chan synovialjoints
3 months 2 weeks ago
Interpreting Hepatis B serology results. Hyrich K #EULAR2024 @RheumNow https://t.co/boXw2XCI2m
Dr. Antoni Chan synovialjoints
3 months 2 weeks ago
Approach to TB screening prior
to commencing biologics. Hyrich K #EULAR2024 @RheumNow https://t.co/j3PI0PHpqW
Dr. Antoni Chan synovialjoints
3 months 2 weeks ago
New imaging technique PET/CT imaging with 68Gallium-labelled Fibroblast Activation Protein Inhibitor-04 (68Ga-FAPI-04) enables the visualization of fibroblast activation in vivo. No correlations with MSUS findings were found. Fibroblast activation detected by 68Ga-FAPI-04-PET/CT… https://t.co/4VTF1YDzYd https://t.co/Y8Hmlf3sWl
Dr. Antoni Chan synovialjoints
3 months 2 weeks ago
Cycle or swap 2? Post failure to a first TNFi in patients with PsA, there was no difference in cycle versus swap to IL17i for drug retention rate or disease activity. In male PsA patients a cycle strategy had a longer drug retention rate compared to a swap (IL-17i) strategy.… https://t.co/5BykvDwFWV https://t.co/GfcnIltV2A
Mrinalini Dey DrMiniDey
3 months 2 weeks ago
Prof Hellmich takes us through “What is new?” In ANCA #vasculitis
A tour de force in management strategies and, continuing a theme of #EULAR2024, ends with a study suggesting the potential of #CAR-T!
@RheumNow https://t.co/K3dDqZhUvD
Janet Pope Janetbirdope
3 months 2 weeks ago
What is better for #Rx of
#osteoporosis?
#Denosumab or ##Zoledronic acid?
#Prolia compared to #Aclasta
Giant admin US data of 125,000 Rx niaive women with #OP
▶️Prolia has LESS fractures!
POS0583 #EULAR2024 @eular_org @RheumNow https://t.co/eo1ny2VIRf
Mrinalini Dey DrMiniDey
3 months 2 weeks ago
✨ Delighted to be chairing the session on newly diagnosed #RMDs in the PARE programme this afternoon, featuring a fantastic panel of speakers!
👥 Perfect for patients and clinicians alike!
👇🏼 All details below- hope to see you there
@RheumNow #EULAR2024 https://t.co/8RmcH8qprJ
Janet Pope Janetbirdope
3 months 2 weeks ago
What is better in #PsA
#psoriatic #arthritis
#TNFi or #apremilast #PDE4i
#COREVITAS database study in #PsA
YOU can guess the answer!
1st line advanced RxTNFi lasts longer - retention
Vs PDE4i
#EULAR2024 @RheumNow @eular_org
POS0990 https://t.co/VmYG6Rj87c
Dr. Antoni Chan synovialjoints
3 months 2 weeks ago
Cycle or Swap? The swap strategy (SG) (i.e. from TNFi to IL17i) had higher retention rates compared to the change strategy (CG) choice in PsA patients who failed the first line of advanced treatment. The 5 years retention rate in SG was higher than in CG (57,8% vs 45,2%; p=0.1).… https://t.co/pH5rFI00vK https://t.co/XqTHO1tIr3
Bella Mehta bella_mehta
3 months 2 weeks ago
Discovery in joint and skin disease - PsA
Three different clusters #EULAR2024 @RheumNow https://t.co/Nj5HZOVqas
Janet Pope Janetbirdope
3 months 2 weeks ago
Predicting who will develop
▶️#GCA
In #Swedish study with
#PMR
⬆️ in HIGH ESR/CRP
⬆️female
⬇️ if hip pain/stiffness
Not all sig 1 mo after #prednisone started
Only 9% with #polymyalgia #rheumatica developed #GCA
? ⬇️GCA % in PMR over time
#POS0411 @eular_org @RheumNow https://t.co/UMhxlYd0Pv
Dr. John Cush RheumNow
3 months 2 weeks ago
EULAR 2024 Highlights: Friday’s Recap with RheumNow https://t.co/r46kiGalBh
Dr. John Cush RheumNow
3 months 2 weeks ago
RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our faculty.
